H.R. 10370
Ailani Myers Accelerating Innovation in Medicine to Cure Kids with Cancer Act
Sponsor: Michael T. McCaul
2 cosponsors
Official summary
No official summary yet.
Text of the bill
I Federal Government Efforts
II Department of Health and Human Services Efforts
(a) In general. The NCI Director shall support, in coordination with the Coordinator, the development and application of artificial intelligence to accelerate progress in pediatric cancer research and care, including through the CCDI.
(b) Data readiness. In carrying out subsection (a), the NCI Director shall—
(1) expand and improve the artificial intelligence readiness of the data platforms and tools of the CCDI Data Ecosystem;
(2) consolidate and harmonize data from multiple sources to enable such data to be analyzed using artificial intelligence; and
(3) develop data standards and technical approaches necessary for the use of artificial intelligence with the data described in paragraphs (1) and (2).
(c) Research and analysis. In carrying out subsection (a), the NCI Director shall support research on pediatric cancer using artificial intelligence—
(1) to improve predictive modeling of patient response, disease progression, and treatment toxicity;
(2) to derive novel diagnostic, prognostic, and therapeutic biomarkers from molecular and imaging data; and
(3) to carry out research projects, including projects carried out at cancer centers designated by the National Cancer Institute.
(d) Clinical trials. In carrying out subsection (a), the Secretary shall support the use of multimodal data and artificial intelligence to improve the design, participant recruitment and selection, administration, conduct, and interpretation of clinical trials for medical products intended to diagnose, treat, prevent, or cure pediatric cancer.
(e) Relationship to CCDI components. Activities under this section shall supplement, and not supplant, the components described in section 201(b).
(f) Dissemination. The Secretary shall make methods, tools, data standards, and technical approaches developed under this section available to other programs of the National Cancer Institute, to other Federal departments and agencies, and, as appropriate, to the public.
III General Provisions